Business Combinations - Summary of Revenue and Operating Income or Loss (Details) $ in Thousands	9 Months Ended
Sep. 30, 2021 USD ($)
Business Acquisition [Line Items]
Net Sales	$ 11,657
Operating Income (loss)	(953)
FF Gene Biotech
Business Acquisition [Line Items]
Net Sales	4,556
Operating Income (loss)	(1,612)
Cytometry Specialists, Inc
Business Acquisition [Line Items]
Net Sales	7,101
Operating Income (loss)	$ 659

The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(3)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

Name:	us-gaap_BusinessAcquisitionsProFormaRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration